Human Health raises €4.7M in precision health funding round

Europe’s digital health sector continues its robust funding trajectory as regulatory tailwinds and an ageing population create unprecedented opportunities for precision medicine platforms. The latest beneficiary of this trend is Human Health, which has secured €4.7 million in seed funding led by LocalGlobe to advance its patient-first approach to precision healthcare delivery.

The funding underscores growing investor confidence in European healthtech startups that prioritise patient outcomes over traditional healthcare metrics. Human Health’s platform represents a shift towards personalised medicine that could reshape how Europeans access and receive healthcare services across fragmented national systems.

LocalGlobe leads precision health funding with strategic vision

LocalGlobe’s decision to lead this round reflects the London-based VC’s thesis around backing European founders who tackle complex, regulated markets with technology-first solutions. The firm, known for early investments in successful European scale-ups, sees significant potential in Human Health’s approach to precision medicine.

“We’re backing a team that understands the intricacies of European healthcare systems whilst building technology that can scale across borders,” said a LocalGlobe partner familiar with the investment. The VC’s portfolio already includes several healthtech companies that have successfully navigated European regulatory requirements whilst expanding internationally.

This seed round positions Human Health alongside other European precision health startups that have attracted significant venture capital in recent months. The €4.7 million figure sits comfortably within the typical range for European healthtech seed rounds, which have averaged €3-6 million over the past 18 months according to industry data.

Platform targets European healthcare transformation

Human Health’s patient-first precision platform addresses a critical gap in European healthcare delivery, where fragmented systems often struggle to provide personalised treatment pathways. The startup’s technology aims to bridge this divide by leveraging data analytics and machine learning to deliver tailored health insights directly to patients and healthcare providers.

The funding will accelerate product development and support the company’s expansion across key European markets, where regulatory frameworks like GDPR provide both challenges and competitive advantages for data-driven healthcare solutions. Human Health’s approach to data privacy and patient consent positions it well for the increasingly regulated European healthtech landscape.

“Our vision extends beyond traditional healthcare boundaries,” explained the company’s leadership team. “We’re building a platform that empowers patients with actionable insights whilst providing healthcare professionals with the tools they need to deliver truly personalised care.” The platform’s focus on patient empowerment aligns with broader European policy initiatives around patient rights and healthcare digitalisation.

With this funding secured, Human Health joins a growing cohort of European healthtech companies that are redefining precision medicine for the continent’s unique regulatory and cultural landscape. The company’s patient-centric approach could prove particularly valuable as European healthcare systems increasingly prioritise preventive care and personalised treatment protocols.

More digital health: see the best digital health events in Europe 2027, ranked by attendance.